Allakos Inc.
| NASDAQ: ALLK | Healthcare / Biotechnology / USA |
| 2.16 | +0.3400 | +18.68% | Vol 1.08M | 1Y Perf -77.08% |
| Nov 29th, 2023 16:00 DELAYED |
| BID | 2.14 | ASK | 2.22 | ||
| Open | 1.82 | Previous Close | 1.82 | ||
| Pre-Market | 2.23 | After-Market | - | ||
| 0.07 3.24% | - - |
| Target Price | 6.83 | Analyst Rating | Moderate Buy 2.50 | |
| Potential % | 216.20 | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12 mo. | -/-/-100 | Value Ranking | — - | |
| Insiders Value % 3/6/12 mo. | -/-/-100 | Growth Ranking | ★★★★ 59.76 | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/-100 | Income Ranking | — - | |
| Price Range Ratio 52W % | 9.44 | Earnings Rating | Strong Sell | |
| Market Cap | 188.95M | Earnings Date | 6th Nov 2023 | |
| Alpha | -0.01 | Standard Deviation | 0.31 | |
| Beta | 0.63 |
Today's Price Range 1.822.17 | 52W Range 1.488.73 |
Summary:
Neutral
| Technical Indicators: | Neutral |
| Moving Averages: | Neutral |
| Performance | |||
|---|---|---|---|
| 1 Week | 25.58% | ||
| 1 Month | 18.03% | ||
| 3 Months | -26.28% | ||
| 6 Months | -54.53% | ||
| 1 Year | -77.08% | ||
| 3 Years | -97.98% | ||
| 5 Years | -96.33% | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -34.37 | |||
ROE last 12 Months | -94.18 | |||
ROA (5Y Avg) | -19.76 | |||
ROA last 12 Months | -78.61 | |||
ROC (5Y Avg) | - | |||
ROC last 12 Months | -76.37 | |||
Return on invested Capital Q | -9.44 | |||
Return on invested Capital Y | -17.52 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | - |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -1.10 | ||||
| 1.78 | ||||
| - | ||||
| - | ||||
| -2.50 | ||||
| -5.38 | ||||
| 1.78 | ||||
| 4.04 | ||||
| 337.99M | ||||
| Forward PE | -0.98 | |||
| PEG | -0.04 |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 11.80 | ||||
| 12.30 | ||||
| 0.12 | ||||
| 0.14 | ||||
| - | ||||
| Leverage Ratio | 1.30 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 0.00 | ||||
| 0.00 | ||||
| - | ||||
| - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q02 2023 | -0.49 | -0.41 | 16.33 |
| Q01 2023 | -0.49 | -0.49 | 0.00 |
| Q04 2022 | -0.56 | -0.50 | 10.71 |
| Q03 2022 | -0.78 | -0.53 | 32.05 |
| Q02 2022 | -0.87 | -0.90 | -3.45 |
| Q01 2022 | -1.71 | -3.60 | -110.53 |
| Q04 2021 | -1.34 | -1.73 | -29.10 |
| Q03 2021 | -1.12 | -1.16 | -3.57 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 12/2023 QR | -0.53 | -10.42 | Negative |
| 12/2023 FY | -1.87 | -3.89 | Negative |
| 3/2024 QR | -0.50 | -6.38 | Negative |
| 12/2024 FY | -1.84 | 1.08 | Positive |
| Next Report Date | - |
| Estimated EPS Next Report | -0.46 |
| Estimates Count | 5 |
| EPS Growth Next 5 Years % | 26.70 |
| Volume Overview | |
|---|---|
| Volume | 1.08M |
| Shares Outstanding | 87.48K |
| Shares Float | 53.77M |
| Trades Count | 9.41K |
| Dollar Volume | 2.26M |
| Avg. Volume | 621.67K |
| Avg. Weekly Volume | 406.65K |
| Avg. Monthly Volume | 499.09K |
| Avg. Quarterly Volume | 959.27K |
Allakos Inc. (NASDAQ: ALLK) stock closed at 2.16 per share at the end of the most recent trading day (a 18.68% change compared to the prior day closing price) with a volume of 1.08M shares and market capitalization of 188.95M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 114 people. Allakos Inc. CEO is Robert Alexander.
The one-year performance of Allakos Inc. stock is -77.08%, while year-to-date (YTD) performance is -74.35%. ALLK stock has a five-year performance of -96.33%. Its 52-week range is between 1.475 and 8.73, which gives ALLK stock a 52-week price range ratio of 9.44%
Allakos Inc. currently has a PE ratio of -1.10, a price-to-book (PB) ratio of 1.78, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of -0.04, a ROA of -78.61%, a ROC of -76.37% and a ROE of -94.18%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from Allakos Inc., there were 3 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-0.46 for the next earnings report. Allakos Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Allakos Inc. is Moderate Buy (2.5), with a target price of $6.83, which is +216.20% compared to the current price. The earnings rating for Allakos Inc. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Allakos Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Allakos Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 13.26, ATR14 : 0.17, CCI20 : 103.51, Chaikin Money Flow : 0.03, MACD : -0.05, Money Flow Index : 48.70, ROC : 24.14, RSI : 58.35, STOCH (14,3) : 97.87, STOCH RSI : 1.00, UO : 53.06, Williams %R : -2.13), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Allakos Inc. in the last 12-months were:
Allakos Inc.
Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's lead program, AK002, an antibody that targets Siglec-8, an inhibitory receptor found on eosinophils and mast cells. In preclinical and clinical studies, AK002 has been shown to deplete eosinophils and inhibit mast cells.
CEO: Robert Alexander
Telephone: +1 650 597-5002
Address: 975 Island Drive, Redwood City 94065, CA, US
Number of employees: 114
TipRanks News for ALLK
Tue, 31 Oct 2023 04:50 GMT Analysts Offer Insights on Healthcare Companies: Allakos (ALLK), Pro Medicus Limited (OtherPMCUF) and Exelixis (EXEL)
- TipRanks. All rights reserved.Wed, 27 Sep 2023 04:55 GMT Promising Prospects for Allakos Innovative Monoclonal Antibodies: A Strong Buy Rating
- TipRanks. All rights reserved.Thu, 10 Aug 2023 07:26 GMT Allakos (ALLK) Initiated with a Sell at Barclays
- TipRanks. All rights reserved.
